Perez-Gracia, Jose Luis https://orcid.org/0000-0003-4941-9075
Mellado, Begoña
Hansen, Aaron Richard https://orcid.org/0000-0002-2363-8707
Alonso-Gordoa, Teresa
Gomez-Roca, Carlos https://orcid.org/0000-0002-8043-2529
Løvendahl Eefsen, Rikke
Negrier, Sylvie
Suárez, Cristina
Lee, Jae-Lyun
Hussain, Arif
Pedrazzoli, Paolo
Moreno, Victor https://orcid.org/0000-0001-6099-4236
Rodriguez-Vida, Alejo
Sosman, Jeffrey Alan
Waddell, Tom
Bedke, Jens
Park, Se Hoon https://orcid.org/0000-0001-5084-9326
Sznol, Mario https://orcid.org/0000-0003-4137-9662
Spychaj, Lukasz
Andersson, Emilia
Julien-Laferriere, Alice
Cheng, Wei-Yi
Watson, Carl
Silva, Ana Patricia
Heichinger, Christian
Staedler, Nicolas https://orcid.org/0000-0001-8212-7459
Sleiman, Nassim
Dejardin, David
Boetsch, Christophe
Evers, Stefan
Vardar, Taner
Ardeshir-Tandon, Caroline
Dorado Pérez, Jorge
Charo, Jehad https://orcid.org/0000-0002-5409-9160
Keshelava, Nino
Kraxner, Anton
Teichgräber, Volker
Powles, Thomas
Clinical trials referenced in this document:
Documents that mention this clinical trial
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
https://doi.org/10.1136/jitc-2025-012466
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd (No grant number is applicable)